In last trading session, Stoke Therapeutics Inc (NASDAQ:STOK) saw 1.63 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $8.74 trading at -$0.56 or -6.02% at ring of the bell on the day assigns it a market valuation of $462.93M. That closing price of STOK’s stock is at a discount of -101.14% from its 52-week high price of $17.58 and is indicating a premium of 41.19% from its 52-week low price of $5.14.
For Stoke Therapeutics Inc (STOK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.20. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.53 in the current quarter.
Stoke Therapeutics Inc (NASDAQ:STOK) trade information
Upright in the red during last session for losing -6.02%, in the last five days STOK remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $8.74 price level, adding 21.33% to its value on the day. Stoke Therapeutics Inc’s shares saw a change of -20.76% in year-to-date performance and have moved -14.81% in past 5-day. Stoke Therapeutics Inc (NASDAQ:STOK) showed a performance of -10.82% in past 30-days.
Wall Street analysts have assigned a consensus price target of 26.5 to the stock, which implies a rise of 67.02% to its current value. Analysts have been projecting 18 as a low price target for the stock while placing it at a high target of 35. It follows that stock’s current price would drop -105.95% in reaching the projected high whereas dropping to the targeted low would mean a loss of -105.95% for stock’s current value.
Stoke Therapeutics Inc (STOK) estimates and forecasts
This year revenue growth is estimated to rise 104.06% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 4.2M for the same. And 4 analysts are in estimates of company making revenue of 2.83M in the next quarter. Company posted 2.8M and 4.22M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -44.06% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 15.21% while estimates for its earnings growth in next 5 years are of -3.38%.
Stoke Therapeutics Inc (NASDAQ:STOK)’s Major holders
SKORPIOS TRUST is the top institutional holder at STOK for having 10.84 million shares of worth $146.5 million. And as of 2024-06-30, it was holding 19.445 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 5.41 million shares on 2024-06-30. The number of shares represents firm’s hold over 11.6963 of outstanding shares, having a total worth of $73.08 million.
